Bladder/Urothelial Cancer
Back To Top
|
| |
| EFC6668 (Age 18 or above) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| CCRC: Randomized Study of Larotaxel + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer |
|
|
| |
| PHII-75 (Age 18 or above) (partial closure) (Patients currently in screening will complete accrual, no further patients to be consented at this time) |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: A Phase I/II Study of E7389 Halichondrin B Analog in Metastatic Urothelial Tract Cancer and Renal Insufficiency (NCI #7435) |
|
|
| |
| S0337 |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer |
|
|
| |
|
Brain Cancer/Metastases
Back To Top
|
| |
| ACNS02B1 (Age up to 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Pre-Clinical Pharmacology in Surgical Brain Tumor Specimens |
| |
| ACNS02B3 (Age 1 - 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens |
| |
| ACNS0332 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients |
| |
| ANBL0032 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Randomized Study of Chimeric Anti-GD-2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue |
| |
| ANBL00B1 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Neuroblastoma Biology Studies |
| |
| COG 9346 (Age 6 mos - 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Hepatoblastoma Biology Study and Tissue Bank - A Non-Therapeutic Study |
| |
| RTOG 0614 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CCRC: A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy |
|
|
| |
| UCDCC#208 (Age 18 or above) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas |
|
|
| |
|
Breast Cancer
Back To Top
|
| |
| CALGB 40101 (Age 18 or above) |
| Clinical research coordinator: Steven Swaim - (530) 751-4270 ext.1579 / (916) 762-2087 |
| CCRC: Cyclophosphamide and Doxorubicin (CA X 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study |
|
|
| |
| CALGB 40302 (Age 18 or above) (temporary closure) (Pending establishment of research billing procedures.) |
| Clinical research coordinator: Trish Foley - (530) 582-6450 / (530) 582-6430 |
| CIRB: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer |
|
|
| |
| CALGB 40601 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer |
|
|
| |
| CCSO001 (Age 18 or above) |
| Clinical research coordinator: Abby Olusanya - (916)734-7502 / (916) 762-0511 |
| Tumescent Mastectomy: A Prospective Comparison to Standard Mastectomy Technique |
| |
| CCSO003 |
| Clinical research coordinator: Abby Olusanya - (916)734-7502 / (916) 762-0511 |
| Reducing Extremity Lymphedema through Axillary Lymphatic Preservation (RELAPSE) |
| |
| CZOL446E2352 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Prospective, Randomized, Double-Blind, Stratified, Multi-Center, 2-Arm Trial of the Continued Efficacy and Safety of Zometa (Every 4 Weeks vs. Every 12 Weeks) in Patients with Documented Bone Metastases From Breast Cancer |
| |
| E5103 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Kami Kazel - (916) 734-5039 / (916) 762-4224 |
| CCRC: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer |
| |
| LPT 111110 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women with ErbB2 Overexpressing Metastatic Breast Cancer |
|
|
| |
| MAP.3 (Age 60 or above) |
| Clinical research coordinator: Denise Macias - (916) 734-3219 |
| Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| |
| MAP.3Bone (Age varies) |
| Clinical research coordinator: Denise Macias - (916) 734-3219 |
| Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| |
| N063D (Age 18 or above) (temporary closure) (Design 1 closed to accrual) |
| Clinical research coordinator: Kami Kazel - (916) 734-5039 / (916) 762-4224 |
| ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer |
|
|
| |
| NEO3-04 (Age 18 or above) |
| Clinical research coordinator: Abby Olusanya - (916)734-7502 / (916) 762-0511 |
| A Phase IV Study to Evaluate the Long-Term Impact of Identifying Tumor-Draining Lymph Nodes Using Lymphoseek® in Patients with Breast Cancer or Melanoma |
| |
| NSABP B-37 |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer |
| |
| PACCT-1 (Age 18 - 75 yrs) |
| Clinical research coordinator: Steven Swaim - (530) 751-4270 ext.1579 / (916) 762-2087 |
| Program for the Assessment of Clinical Cancer Test (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial |
| |
| PHI-63 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer (NCI #8282) |
|
|
| |
| RTOG 0413/NSABP B-39 (Age 18 or above) (partial closure) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) For Women With Stage 0, I, or II Breast Cancer |
| |
| S0221 (Age 18 or above) |
| Clinical research coordinator: Steven Swaim - (530) 751-4270 ext.1579 / (916) 762-2087 |
| A Phase III Trial of Continuous Schedule AC + G vs. Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer |
|
|
| |
| S0307 |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: A Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer |
| |
| S0500 |
| Clinical research coordinator: Steven Swaim - (530) 751-4270 ext.1579 / (916) 762-2087 |
| A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment |
| |
| S0622 (Age 18 or above) |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer |
| |
| TOC4129g (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer |
| |
| UCDCC#186 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Serum Glycan Analysis in Breast Cancer |
| |
| UCDCC#207 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| Phase I Study of Lapatinib (GW572016) in Combination with Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors |
| |
|
Colorectal Cancer
Back To Top
|
| |
| |
| CALGB C80405 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| CCRC: A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab or Cetuximab (C225) for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum |
| |
| Colon |
| CTSU E5202 (Age 18 or above) |
| Clinical research coordinator: Lee Techel - (925) 580-0298 |
| A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers |
| |
| N0147 (Age 18 or above) |
| Clinical research coordinator: Lee Techel - (925) 580-0298 |
| CIRB: A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer |
| |
|
Correlative and Ancillary Studies
Back To Top
|
| |
| AALL05B1 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens |
| |
| AHOD04B1 |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Hodgkin Disease (HD) Banking Study |
| |
| COG 9902 (Age up to 50 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Group Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens - An IRS Protocol |
| |
| GOG 0136 |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Acquisition of Human Gynecologic Specimens and Serum to Be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer |
| |
| RTOG 0514 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| Establishment of a Head and Neck Cancer Tissue/Specimen Bank |
| |
| S0309 |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Myeloma Specimen Repository Protocol, Ancillary |
| |
| S9245 |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary |
|
|
| |
| S9910 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary |
| |
| S9925 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: Ancillary, Lung Cancer Specimen Repository Protocol |
| |
| UCDCC#155 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood |
| |
| UCDCC#183 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer |
| |
| UCDCC#186 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Serum Glycan Analysis in Breast Cancer |
| |
|
Endometrial Cancer
Back To Top
|
| |
| PHII-80 (Age 18 or above) (partial closure) (Carcinosarcoma (malignant mixed mullerian tumor) arm is permanently closed; leiomyosarcoma arm is in stage II and open to accrual.
) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas (NCI#7502)(ARD6836) |
| |
| PHII-89 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma (NCI 7713; PHL-062) |
| |
| PHII-92 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Trial of CCI-779 and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular carcinoma, Carcinoid or Islet Cell Cancer (NCI #8233) |
| |
|
Esophageal Cancer
Back To Top
|
| |
| RTOG 0436 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery |
|
|
| |
|
Head and Neck Cancers
Back To Top
|
| |
| ACNS0331 |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Phase III Double Randomized Trial Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma |
| |
|
Hodgkin Lymphoma
Back To Top
|
| |
| AHOD04B1 |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Hodgkin Disease (HD) Banking Study |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
|
Kidney Cancer
Back To Top
|
| |
| AREN03B2 (Age 1 - 30 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Renal Tumors Classification, Biology, and Banking Study |
| |
| AREN0532 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor |
| |
| E2804 (Age 18 or above) (partial closure) |
| Clinical research coordinator: Steven Swaim - (530) 751-4270 ext.1579 / (916) 762-2087 |
| CCRC: The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma |
| |
| E2805 (Age 18 or above) |
| Clinical research coordinator: Lee Techel - (925) 580-0298 |
| CCRC: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma |
| |
| VEG108844 (Age 18 or above) |
| Clinical research coordinator: Garrett Tichauer - (916) 734-3758 / (916) 762-4124 |
| CCRC: VEG108844: A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma |
|
|
| |
|
Leukemia
Back To Top
|
| |
| |
| AALL0331 (Age 1 - 9 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Phase III Randomized Study of Different Combination Chemotherapy Regimens in Pediatric Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia |
| |
| AALL03B1 (Age 1 - 22 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Classification of Acute Lymphoblastic Leukemia |
| |
| AALL03N1 (Age up to 21 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia |
| |
| PHI-57 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias (NCI #7689) |
| |
| PHII-73 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: A Phase II Study of VEGF Trap (NSC 724770) in Patients with MDS (NCI #7518) |
| |
| S9007 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: Cytogenetic Studies in Leukemia Patients |
| |
| UC Berkeley (Age up to 14 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Molecular Epidemiology Childhood Leukemia |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
| ALL |
| AALL0232 (Age 16 - 30 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| High Risk B-Precursor Acute Lymphoblastic Leukemia |
| |
| AALL0433 (Age varies) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies |
| |
| AALL0434 (Age 1 - 30 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) |
| |
| CCPO001 (Age up to 18 yrs) |
| Clinical research coordinator: - |
| Development of Leukemia Stem Cell Targeted Therapy in Childhood Leukemia |
| |
| AML |
| AAML0531 (Age up to 29 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults |
| |
| CLTR0308-204 (Age varies) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients with Untreated AML 60-75 Years of Age |
|
|
| |
| CLTR0308-205 (Age varies) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Phase IIB, Multicenter, Randomized, Open-Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adult Patients ≤60 Years Old with AML in First Relapse Following an Initial CR >1 Month Duration |
|
|
| |
| CLL |
| CALGB C10501 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease |
| |
|
Liver Cancer
Back To Top
|
| |
| PHII-83 (Age 18 or above) (temporary closure) (5/19/09: closed for interim analysis) |
| Clinical research coordinator: Patsy Pasquinelli - (916) 734-5129 / (916) 762-7213 |
| CCRC: A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma (NCI #7792) |
| |
| PHII-92 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Trial of CCI-779 and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular carcinoma, Carcinoid or Islet Cell Cancer (NCI #8233) |
| |
| S0802 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| CCRC: A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) |
| |
|
Lung Cancer
Back To Top
|
| |
| |
| S9925 (Age 18 or above) |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: Ancillary, Lung Cancer Specimen Repository Protocol |
| |
| UCDCC#155 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood |
| |
| Non-Small Cell |
| 05-10-277 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) versus Single Agent Pemetrexed (Alimta) in Patients with Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| |
| 109493 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of RecMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer |
| |
| A4021016 (Age 18 or above) (temporary closure) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: Randomized, Open Label, Phase III Trial of CP-751,871 Plus Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients with Non-Small Cell Lung-Cancer |
| |
| CALGB 140503 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (<= 2 cm) Peripheral Non-Small Cell Lung Cancer |
| |
| CCRD004 (Age 18 or above) |
| Clinical research coordinator: John Brock - (916) 734-3101 / (916) 762-6902 |
| FDG-PET and Molecular Markers for Early Prediction of Efficacy in Advanced NSCLC Patients Treated with Erlotinib |
| |
| E1505 (Age 18 or above) |
| Clinical research coordinator: Trish Foley - (530) 582-6450 / (530) 582-6430 |
| CCRC: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) |
| |
| H3E-MC-JMIG (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology (PROCLAIM) |
| |
| PHII-74 (Age 18 or above) (Open to taxane sensitive patients only; effective 10.20.09, accrual completed if current patients in screening enroll, no further consents to be given out at this time) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: A Phase II Study of the Halichondrin B Analog E7389 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a Taxane (NCI #7437) |
| |
| RTOG 0618 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase II Trial of Sterotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer |
| |
| S0424 (Age 18 or above) (partial closure) (Partial Closure: Smoker Strata closed due to meeting accrual goal.) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| CCRC: Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men |
| |
| S0533 (Age 18 or above) (partial closure) (High risk stratum (Stratum 2) is permanently closed to accrual.) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CCRC: A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer |
| |
| S0635 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (AdenBAC) |
| |
| S0636 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas |
| |
| S0709 (Age 18 or above) |
| Clinical research coordinator: Trish Foley - (530) 582-6450 / (530) 582-6430 |
| CCRC: A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics |
| |
| S0720 |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) |
| |
| S0819 |
| Clinical research coordinator: Trish Foley - (530) 582-6450 / (530) 582-6430 |
| CCRC: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) |
| |
| UCDCC#177 (Age 18 or above) (Phase II portion open to accrual) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| A Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors with an Emphasis on Non-Small Cell Lung Cancer (NSCLC)(OSI4267s) |
| |
| UCDCC#185 (Age 18 or above) (Phase II portion open to accrual ) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| A Phase I/II Trial of Abraxane TM ® (ABI-007) and ALIMTA (Pemetrexed) in Advanced Solid Tumors with Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer (H3E-US-1017) |
| |
| XL184-202 (Age 18 or above) (temporary closure) (Phase I accrual complete) |
| Clinical research coordinator: Patsy Pasquinelli - (916) 734-5129 / (916) 762-7213 |
| CCRC: A Phase 1/2 Study of XL184 with or without Erlotinib in Subjects with Non-Small Cell Lung Cancer |
| |
| Z4032 |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection Plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3 cm or Smaller |
| |
| Z4033 (Age varies) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Pilot Study of Radiofrequency Ablation in High-Risk Patients with Stage IA Non-Small Cell Lung Cancer |
| |
| Small Cell |
| CTSU C30610 (Age 18 or above) |
| Clinical research coordinator: Courtney Eddings - (916) 734-3604 / (916) 762-4248 |
| CCRC: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide |
| |
| M06-822 (Age 18 or above) (Phase II open to accrual) |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: A Phase I/IIA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies |
| |
| PHII-90 (Age 18 or above) (temporary closure) (Study temporarily closed for interim analysis ) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer (NCI# 8027) |
| |
| UCDCC#214 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| Phase I Trial of Carboplatin and Etoposide in Combination with Everolimus (RAD001) in Advanced Solid Tumors, with Emphasis on Small Cell Lung Cancer (SCLC) |
| |
|
Melanoma
Back To Top
|
| |
| E1697 (Age varies) |
| Clinical research coordinator: Lee Techel - (925) 580-0298 |
| CCRC: Phase III Randomized Study of Four Weeks High Dose IFN-alpha 2b in Stage T2b No, T3a-b, T4a-b No, and T1-4, N1a, 2a, 3 (microscopic) Melanoma |
| |
| NEO3-04 (Age 18 or above) |
| Clinical research coordinator: Abby Olusanya - (916)734-7502 / (916) 762-0511 |
| A Phase IV Study to Evaluate the Long-Term Impact of Identifying Tumor-Draining Lymph Nodes Using Lymphoseek® in Patients with Breast Cancer or Melanoma |
| |
| S0438 (Age 18 or above) (partial closure) (Arm 2 permanently closed to accrual. Arm 1 (BAY 43-9006/CCI-779) will be permanently closed to accrual effective 11/15/09.) |
| Clinical research coordinator: Steven Swaim - (530) 751-4270 ext.1579 / (916) 762-2087 |
| CCRC: A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus: NSC-683864) or R115777 (Tipifarnib: NSC-702818) in Metastatic Melanoma |
| |
|
Mesothelioma
Back To Top
|
| |
| PHII-65 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase II Study of AZD2171 in Patients with Malignant Mesothelioma (NCI #7103) |
| |
|
Miscellaneous
Back To Top
|
| |
| PEP-07-214-01-PEP2 (Age 18 or above) |
| Clinical research coordinator: John Linder - (916) 703-5221 / (916) 762-5708 |
| Latino Palliative Care Cancer Study |
| |
|
Multiple Myeloma
Back To Top
|
| |
| CZOL446EUS129 |
| Clinical research coordinator: Barbara Noble - (916) 734-2389 / (916) 762-3778 |
| Bone Marker Directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma |
| |
| E1A05 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®)- Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen |
| |
| S0115 (Age varies) (temporary closure) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) for Patients with AL Amyloidosis or High Risk (Greater Than or Equal to Age 70 or Poor Renal Function) Patients with Multiple Myeloma (A BMT Study) |
| |
| S0309 |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Myeloma Specimen Repository Protocol, Ancillary |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
|
Non-Hodgkin's Lymphoma
Back To Top
|
| |
| CALGB 50303 (Age 18 or above) |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: Phase III Randomized Study of R-CHOP vs. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas |
| |
| CRAD001N2201 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| An Open-Label, Single-Arm Phase II Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma (EUDRACT 2007-005700-40) |
| |
| PHI-58 (Age 18 or above) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| CCRC: Phase I Study of GX15-070 (NSC# 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma (NCI #7943) |
| |
| PHI-60 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction (NCI #8063) |
| |
| UCDCC#196 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients with Hematological Malignancies Conditioned with Fludarabine and Busulfan |
| |
| UCDCC#197 (Age 18 or above) |
| Clinical research coordinator: Chris Reed-Pease - (916) 734-7094 / (916) 762-7970 |
| CCRC: A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular NHL (RV 0163) |
| |
|
Ovarian/Peritoneal Cancer
Back To Top
|
| |
| 20070182 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| CCRC: A Phase Ib Study of AMG 386 in Combination with Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects with Advanced Recurrent Epithelial Ovarian Cancer |
| |
| GOG 0212 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy |
| |
| PHI-63 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer (NCI #8282) |
|
|
| |
| PHII-92 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Trial of CCI-779 and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular carcinoma, Carcinoid or Islet Cell Cancer (NCI #8233) |
| |
| UCDCC#183 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer |
| |
|
Pancreatic Cancer
Back To Top
|
| |
| PHI-63 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer (NCI #8282) |
|
|
| |
| PHII-92 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Trial of CCI-779 and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular carcinoma, Carcinoid or Islet Cell Cancer (NCI #8233) |
| |
| UCDCC#211 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer (OSI4132s) |
| |
|
Phase I
Back To Top
|
| |
| PHI-53 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies (NCI#7251) |
| |
| PHI-54 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors (NCI#7540) |
| |
| PHI-55 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors (NCI#7427) |
| |
| PHI-60 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction (NCI #8063) |
| |
| PHI-61 (Age 18 or above) |
| Clinical research coordinator: George Bennig - (916) 734-4913 / (916) 762-4204 |
| CCRC: A Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies (NCI #7967) |
| |
| UCDCC#207 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| Phase I Study of Lapatinib (GW572016) in Combination with Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors |
| |
| UCDCC#214 (Age 18 or above) |
| Clinical research coordinator: Natasha Perkins - (916) 734-8409 / (916) 762-0819 |
| Phase I Trial of Carboplatin and Etoposide in Combination with Everolimus (RAD001) in Advanced Solid Tumors, with Emphasis on Small Cell Lung Cancer (SCLC) |
| |
|
Prostate Cancer
Back To Top
|
| |
| CALGB 90203 (Age 18 or above) |
| Clinical research coordinator: Daniel Robles - (916) 734-8291 / (916) 762-7251 |
| CCRC: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer |
| |
| COU-AA-302 (Age 18 or above) |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer |
|
|
| |
| E3805 (Age 18 or above) |
| Clinical research coordinator: Steven Swaim - (530) 751-4270 ext.1579 / (916) 762-2087 |
| CCRC: CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer |
| |
| PHI-63 (Age 18 or above) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| CCRC: A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2 Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer (NCI #8282) |
|
|
| |
| PHII-84 (Age 18 or above) |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy (NCI #7659) |
| |
| RTOG 0534 |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy |
|
|
| |
| RTOG 0622 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy |
|
|
| |
| S0421 |
| Clinical research coordinator: Grace Loredo - (916) 734-3691 / (916) 762-4182 |
| CCRC: A Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer |
| |
| UCDCC#215 (Age 18 or above) |
| Clinical research coordinator: Patsy Pasquinelli - (916) 734-5129 / (916) 762-7213 |
| Randomized Phase II Trial of Bicalutamide +/- RAD001 in Patients with Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy |
|
|
| |
| UCDCC#217 (Age 18 or above) |
| Clinical research coordinator: Jaclyn Morrison - (916) 734-0162 / (916) 762-4297 |
| CCRC: Measurement of 41Ca Kinetics in Humans with Prostate Cancer-Induced Bone Disease |
| |
| UCDCC#218 (Age varies) |
| Clinical research coordinator: Garrett Tichauer - (916) 734-3758 / (916) 762-4124 |
| CCRC: Assessing PSA Rsponse in Low Dose Ketoconazole in Castration Resistant Prostate Cancer Patients Who Have Failed at Least One Prior Systemic Chemotherapy Regimen |
| |
|
Sarcoma
Back To Top
|
| |
| ANBL00P2 (Age up to 12 mos) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Perinatal Neuroblastoma: Expectant Observation. A Children's Oncology Group Pilot Study |
| |
| AOST0331 (Age 5 - 40 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| A Randomized Trial of the European and American Osteosarcoma Study Group to Optimized Treatment Strategies for Resectable Osteosarcoma Base on Histological Response to Pre-Operative Chemotherapy |
| |
| AP23573-07-302 (Age varies) |
| Clinical research coordinator: Karen Schlaier - (916) 734-8814 / (916) 762-9619 |
| A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas |
| |
| ARST0331 (Age up to 49 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Vincristine, Dactinomycin and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma |
| |
| ARST0531 (Age up to 50 yrs) |
| Clinical research coordinator: Wendy Lashway - (916) 734-2780 |
| Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS) |
| |
| PHII-80 (Age 18 or above) (partial closure) (Carcinosarcoma (malignant mixed mullerian tumor) arm is permanently closed; leiomyosarcoma arm is in stage II and open to accrual.
) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas (NCI#7502)(ARD6836) |
| |
| UCDCC#216 (Age 18 or above) |
| Clinical research coordinator: Abby Olusanya - (916)734-7502 / (916) 762-0511 |
| CCRC: Phase I/II Trial of Neoadjuvant Conformal Radiotherapy plus Sorafenib for Patients with Soft Tissue Sarcoma of the Extremity and Body Wall (IST000449) |
| |
|
Supportive Care and Other
Back To Top
|
| |
| RTOG 0433 (Age 18 or above) |
| Clinical research coordinator: Frances Lara - (916) 734-8134 / (916) 762-6282 |
| A Phase III International Randomized Trial of Single vs. Multiple Fractions for Re-Irradiation of Painful Bone Metastases |
| |
|
Uterine Cancer
Back To Top
|
| |
| PHII-80 (Age 18 or above) (partial closure) (Carcinosarcoma (malignant mixed mullerian tumor) arm is permanently closed; leiomyosarcoma arm is in stage II and open to accrual.
) |
| Clinical research coordinator: Joan Houston - (916) 734-8381 / (916) 762-9901 |
| A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas (NCI#7502)(ARD6836) |
| |
| PHII-89 (Age 18 or above) |
| Clinical research coordinator: Ana Ogilvie - (916) 734-1455 / (916) 762-2435 |
| CCRC: A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma (NCI 7713; PHL-062) |
| |
For information about adult cancer clinical trials, please call (916) 734-1455.
For information about clinical trials at other leading cancer centers around the country, please call 1 (800) 4-CANCER.